Table 1.

Baseline characteristics of the patients according to serum hsCRP levelsa

hSCRP Level
All<1 mg/L1–3 mg/L>3 mg/L
Characteristics (n = 1,680)(n = 563)(n = 603)(n = 514)Pb
CRP, median mg/L, (range)1.6 (0.1–272)0.6 (0.1–0.99)1.7 (1–2.99)5.5 (3–272)
Age, median y, (range)59 (31–88)58 (31–82)59 (35–88)59.5 (35–87)0.004
Women, n (%)535 (32)146 (26)154 (26)235 (46)<0.001
Race or ethnic group,cn (%) 
 Non-Hispanic White1,549 (92)518 (92)569 (94)462 (90)0.04
 Non-Hispanic Black88 (5)28 (5)21 (3)39 (7)
 Hispanic29 (2)11 (2)9 (2)9 (2)
 Asian/Pacific Islander/other14 (1)2 (0.3)4 (0.8)8 (1.4)
Current cigarette smoker, n (%)277 (16)54 (10)115 (19)108 (21)<0.001
Body mass indexd28 (15–58)26 (15–43)28 (17–43)31 (19–58)<0.001
 Men28 (15–49)27 (15–43)29 (17–43)30 (20–49)<0.001
 Women28 (18–58)24 (18–41)28 (18–43)30 (19–58)<0.001
Colorectal cancer in a parent, n (%)355 (21)122 (22)136 (23)97 (19)0.3
Findings at baseline colonoscopy
 No. of adenomas2 (1–17)2 (1–11)2 (1–17)2 (1–10)0.24
 At least 1 adenoma ≥1 cm, n (%)719 (43)241 (43)245 (41)233 (45)0.29
 Multiple adenomas, n (%)932 (55)310 (55)341 (57)281 (55)0.80
 Adenoma burden,e cm1.5 (1.2)1.4 (1.2)1.5 (1.3)1.5 (1.2)0.61
History of cardiovascular events,fn (%)237 (14)59 (10)102 (17)76 (15)0.006
History of hypertension, n (%)677 (40)175 (31)261 (43)241 (47)<0.001
History of diabetes, n (%)156 (9)37 (7)55 (9)64 (12)0.004
Use of low-dose aspirin,gn (%)539 (32)177 (31)219 (36)143 (28)0.009
Use of postmenopausal hormones,hn (%)211 (39)31 (21)56 (36)124 (53)<0.001
Use of statins, n (%)421 (25)147 (21)166 (28)108 (21)0.03
Randomized to placebo, n (%)563 (34)192 (34)209 (35)162 (32)0.05
Randomized to celecoxib, 200-mg-bid, n (%)558 (33)175 (31)212 (35)171 (33)0.06
Randomized to celecoxib, 400-mg-bid, n (%)559 (34)196 (35)182 (30)181 (35)0.74
  • aData are expressed as mean (SD) unless otherwise indicated.

  • bTest of difference between hsCRP groups was calculated by ANOVA for continuous variables, χ2 for categorical variables.

  • cRace or ethnic group was determined by the investigator.

  • dBody mass index is the weight in kilograms divided by the square of the height in meters.

  • eThe adenoma burden was defined as the sum of the diameter of all adenomas reported during colonoscopy at baseline.

  • fCardiovascular events were defined as myocardial infarction, cerebrovascular disease, congestive heart failure, angina, and atherosclerotic heart disease.

  • gLow-dose aspirin was defined as ≤325 mg every other day or ≤162.5 mg every day.

  • hPercentage using postmenopausal hormones was calculated among women only.